KaNDy Therapeutics Company
KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone-related conditions.
Last Funding Type:
Series C
Funding Status:
M&A
Headquarters:
Stevenage, Herefordshire, United Kingdom
Founded Date:
2017
Investor Type:
Company
Investment Stage:
N/A
Last Funding Date:
2018-08-29
Total Funding:
$32 589 510
Technology:
Cancer
Employee Number:
1-10
Number Of Exists:
Series C
Estimated Revenue:
$1M to $10M
Investors Number:
5
Industry:
Longevity